Glaxo Has No Current Plans To Spin Off Viiv, But Does Not Rule It Out
Whenever a corporate executive has to publicly state that they will not be spinning something off, it’s generally only a matter of time. This is likely the case with GlaxoSmithKline(GSK) and its majority-owned Viiv Healthcare unit. Viiv, of which Glaxo owns 76.5%, recently filed for approval for its anti-HIV drug, dolutegravir. If the drug is approved, it is… Read More »